Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
Japan
A site selected by Taiho Pharmaceutical Co., Ltd., Aichi A site selected by Taiho Pharmaceutical Co., Ltd., Chiba A site selected by Taiho Pharmaceutical Co., Ltd., Ehime A site selected by Taiho Pharmaceutical Co., Ltd., Hokkaido A site selected by Taiho Pharmaceutical Co., Ltd., Kanagawa A site selected by Taiho Pharmaceutical Co., Ltd., Osaka A site selected by Taiho Pharmaceutical Co., Ltd., Shizuoka A site selected by Taiho Pharmaceutical Co., Ltd., Tokyo A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama